Vertex Inks Another Orkambi Reimbursement Deal After France Says Yes
The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.
You may also be interested in...
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
The European Medicines Agency has received 11 new marketing authorization applications, including three for orphan products from Vertex, MYR Pharmaceuticals and AstraZeneca.
After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.